PenG MIP impact on gross margins
The minimum import price on PenG and its derivatives could impact gross margins by ₹80-100 crore, partially offset by pricing actions in trade generics.
medium · management_commentaryAlkem Laboratories Limited — Q3 FY26
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore (+10.7% YoY) and EBITDA of ₹828 crore (+9% YoY), with EBITDA margin at 22.2%.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Execution risk in Medtech integration
The Occlutech acquisition involves integrating a global Medtech company with different business dynamics, posing execution challenges.
medium · analyst_questionTrade generic business headwinds
The trade generic business has been flattish this year due to competitive pressures, and recovery to high single-digit growth may take time.
low · management_commentaryDenosumab U.S. entry delayed by litigation
U.S. entry for denosumab biosimilars is delayed to end-2026 due to ongoing litigation with Amgen.
medium · management_commentary